로딩 중…
지수 로딩 중…
Enliven Therapeutics, Inc.
ELVN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$58.04+5.89%
2026-08-03
Financials
Valuation Metrics
Enliven Therapeutics, Inc.'s Market Cap is $3.53B. At end of 2025 it was $873M. Ranked #1650 of 3,112 in US market (top 53%), #587 of 1,445 on NASDAQ (top 41%), #95 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.53B | US#1,650/3,112 Sec#95/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-99M | US—/3,112 Sec—/269 |
| Total Assets | $465M | US#2,773/3,112 Sec#166/269 |
| Net Assets | $453M | US#2,325/3,112 Sec#122/269 |
| Value | ||
| P/B | 7.80x | US#2,477/3,112 Sec#187/269 |
| FCF Yield | -1.86% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -21.79% | US#2,541/3,112 Sec#106/269 |
| ROA | -21.25% | US#2,789/3,112 Sec#129/269 |
| Financial Health | ||
| Debt Ratio | 2.53% | US#23/3,112 Sec#4/269 |
| Total Debt | $302000.00 | US#2,963/3,112 Sec#260/269 |
| FCF | $-66M | US#2,510/3,112 Sec#122/269 |
| Cash | $132M | US#2,028/3,112 Sec#154/269 |
| Current Ratio | 40.32x | US#63/3,112 Sec#4/269 |
| Performance | ||
| 1Y Return | 209.88% | US#97/3,112 Sec#30/269 |
| 1M Return | 16.50% | US#232/3,112 Sec#11/269 |
| From 52W High | -2.81% | US#313/3,112 Sec#11/269 |
| 1Y MDD | -36.84% | US#1,795/3,112 Sec#128/269 |
| Trading | ||
| Volume | 2,823,620 shares | US#665/3,112 Sec#58/269 |
| Trading Value | $160M | US#622/3,112 Sec#37/269 |
| Per Share | ||
| EPS | $-1.83 | US—/3,112 Sec—/269 |
| BPS | $8.11 | US#1,928/3,112 Sec#82/269 |